Introduction
Arthritic diseases are common crippling conditions for which there are no cures and few useful treatments. Nevertheless recent research into the biology of rheumatoid arthritis (RA) and osteoarthritis (OA), the two most common forms of arthritis, has identified a number of potentially anti-arthritic proteins with promising antiinflammatory, immunomodulatory or chondroprotective properties. A number of these proteins have been evaluated in animal models of arthritis, with encouraging results.
Clinical application of such mediators is greatly hindered by the lack of a suitable means for delivering them to patients with arthritis. Oral administration of proteins is ineffective, and delivery by injection is inefficient because of the rapidity with which they are cleared. T o circumvent these limitations, we have suggested that instead of delivering the therapeutic proteins themselves, it would be better to deliver the genes that encode them. In this sense, we are proposing gene transfer as a biological drugdelivery system for secreted anti-arthritic proteins [l-41. Although this concept can be extended to include the delivery of other gene products, such as anti-sense RNA or transcription factors, which act intracellularly, the use of genes encoding secreted proteins stands the greatest chance of early success as it can be used in an ex vivo fashion and does not require unreasonably high transduction efficiencies. In this context, the most immediate questions to be Abbreviations used: RA, rheumatoid arthritis; OA, osteoarthritis; IL, interleukin; TNF-m, tumour necrosis factor a ; IL-lRa, IL-1 receptor antagonist; Th, T-helper lymphocyte; SCID, severe combined immunodeficiency.
answered are: which genes are anti-arthritic? Where should they be transferred? How should they be transferred?
Which genes are anti-arthritic? Most data are available for RA, which is a chronic erosive inflammatory condition with important systemic components; it is thought to be autoimmune in nature. Comprehensive treatment of RA requires that both the loss of cartilage and the inflammation within joints be arrested, and that the systemic components of the disease are brought under control.
One therapeutic possibility is to target the co-stimulatory pathways, such as B7/CD28 and CD40/CD40L, which are required for lymphocyte activation [ S ] . Such intervention has the potential not only to suppress unwanted immune reactivity, but also to induce tolerance. The use of soluble ligands and receptors is an attractive approach to achieving this.
Alternative targets are the cytokines that drive many of the intra-articular pathophysiological events [6] . Interleukin (1L)-1 and tumour necrosis factor a (TNF-a) have emerged as key mediators in this respect [7] . Naturally occurring antagonists of these cytokines exist. Soluble forms of both IL-1 receptors and both TNF-a receptors occur at sites of inflammation, whereas IL-1Ra acts as a receptor antagonist [7] . These antagonists and neutralizing antibodies to TNF-o! show anti-arthritic activity in animal models of arthritis, and several have entered human trials [8-101. These trials have illustrated the problems associated with the sustained delivery of therapeutic proteins to patients with chronic conditions. Intravenous loading of the patients was followed several weeks later by a flare [8] , and daily subcutaneous self-injection was
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-unpleasant and associated with reactions at the injection site that caused some participants to leave the trial [lo] . Recent data suggest that in RA there is an imbalance in the activities of T-helper-1 lymphocyte (Th-1) and Th-2 cytokines [6] such that administration of the latter, particularly IL-4 and IL-10, has therapeutic effects. These cytokines show strong anti-arthritic properties in murine models of RA, where they may work by suppressing cell-mediated immunity as well as by inhibiting the synthesis of IL-1 and TNF-a while increasing production of IL-1 Ra
OA is not an autoimmune disease, and the inflammatory component is generally moderate or low. Instead, the major pathology is loss of cartilage. IL-1 and IL-17 [14] are the most potent of the cytokines that induce cartilage breakdown, but the latter is unlikely to be present in the absence of T-lymphocytes. TNF-a and leukaemia inhibitory factor are weaker catabolic agents. IL-lRa, delivered by biweekly intraarticular injection, has recently been shown to protect against the early degenerative changes that occur in a canine model of OA [ 151. An additional way to preserve the cartilaginous surfaces of the joints is to increase the rate of synthesis of the cartilaginous matrix. There are data to suggest that insulin-like growth factor I, basic fibroblast growth factor, transforming growth factor p [ 161 and certain bone-morphogenetic proteins [17] are potent anabolic agents.
Where to transfer anti-arthritic genes?
Arthritis, as its name suggests, is a disease that produces its main pathological effects within joints. This being so, it makes sense to transfer anti-arthritic genes to the affected joints, so that the highest concentrations of the gene products occur intra-articularly. As well as solving the drug-delivery problems described above, intraarticular delivery ensures that extra-articular tissues receive reduced exposure to the gene products. This brings the important advantage of minimizing side effects, a complication for which existing anti-arthritic drugs are notorious.
Because the synovium has a large surface and is in direct contact with the joint space, it is an obvious target for local gene delivery to joints. Certain applications in OA, however, may require gene transfer to chondrocytes. Local intra-articular gene delivery is well suited to conditions such as OA, where few joints are affected and there are no major systemic disturbances. However, because RA is a polyarticular systemic disease, we have also investigated the possibility of introducing anti-arthritic genes into locations where the secreted gene products gain access to the systemic circulation [2-41. Experiments in which such genes are transferred to the haemopoietic stem cells of mice have confirmed that systemic delivery of this nature can result in high circulating levels of biologically active products [ 18, 191 . Additional potential targets include muscle [ZO], lymphocytes [21] and artificial organoids. For systemic delivery, ex vivo gene transfer using retroviruses has been successful for delivery to a number of extra-articular tissues. Direct injection into the bloodstream or accessible solid organs such as muscle should also be possible once problems of immunogenicity and long-term expression have been overcome.
Methods of gene transfer in arthritis
As with other areas of gene therapy, investigators have available a variety of viral and non-viral vectors, and may use them according to in vivo or ex vivo strategies. Screening a variety of vectors for their ability to transfer the EacZ gene into the synovial lining of the rabbit knee joint showed quite clearly
Other issues
Arthritic diseases are chronic and usually follow an unpredictable course of flares and remissions. Any gene treatments should thus aim to achieve prolonged regulated gene expression or be so minimally invasive as to permit frequent repeat dosing. None of these desiderata have yet been met, but the volume of research activity surrounding these issues is such as to permit optimism about future progress.
Preclinical data
Local delivery of cDNAs encoding a number of potentially anti-arthritic genes has been achieved Volume 25
Gene Therapy by ex vivo transfer with a retrovirus and in vivo transfer with adenovirus (Table 1 ). In each case there was evidence of gene expression and an anti-arthritic effect. The strong agreement between the data of four different groups of investigators working independently at different centres using different vectors and different animal models of RA permits considerable optimism about the potential of gene therapy to treat this disease.
The first experimental study investigating the use of gene therapy to treat OA has just been completed. This utilized a dog model, in which transection of the anterior cruciate ligament in one knee joint leads to osteoarthritic changes. Ex vivo transfer of the human IL-1Ra cDNA to the synovial fibroblasts isolated from the lining of the joint 2 days after transection of the ligament protected the articular cartilage from the early degenerative changes that otherwise follow this procedure [32] . OA may also be treated by the transfer of genes to cartilage. The ex vivo transfer of a marker gene to chondrocytes using a retrovirus has just been reported [33] .
In the context of systemic gene delivery for RA, potentially anti-arthritic genes have been transferred to the skeletal muscle [ZO] , haemopoietic stem cells [18, 19] and lymphocytes [21] of mice. Raz et al. [20] injected plasmid DNA encoding IL-1, IL-4 or transforming growth factor / I into murine muscle and were able to increase or decrease the immune responses of the animals depending on the cytokine whose cDNA was transferred. This result is quite remarkable in view of the low levels of gene expression that such procedures generally produce.
Transfer of IL-1Ra and TNF-asRII genes into haemopoietic bone marrow cells in mice led to life-long transgene expression and high sustained serum concentrations of the gene product [ 18, 191 . Certain responses to endotoxin challenge were attenuated in these mice [19] .
Retroviral transfer of the TNF-asRI gene to splenocytes of mice with collagen-induced arthritis was able to inhibit the development of the arthritis that otherwise follows the transfer of these cells to recipients with severe combined immunodeficiency (SCID) [21] . Lymphocytes are an attractive target because they infiltrate rheumatoid synovia, and some subsets may home to joints.
The only preclinical evidence that gene therapy may be effective in human arthritic tissues comes from the results of experiments in which human synovial fibroblasts and human cartilage were co-implanted into SCID mice [34] . Under these conditions, rheumatoid synoviocytes degrade the human cartilage by both direct invasion and stimulating chondrocytic chondrolysis. Prior retroviral transduction of the synoviocytes with the human IL-1Ra gene inhibited the latter process. In these experiments, transgene expression was still evident 60 days after implantation of the cells. This suggests that the expression of human IL-1Ra in rabbit knees is limited to approximately half this value by immune mechanisms.
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The first human trial These promising preclinical findings led to the first human trial of gene therapy for arthritis [35] . A human IL-1Ra cDNA was selected as the gene of choice as it had shown promise in animal 
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Biochemical Society Transactions models and because IL-1Ra protein has such a favourable toxicological profile. Moreover IL-1 Ra protein had already been safely administered to normal human volunteers and to patients with inflammatory conditions. An ex vivo delivery system was selected because of its promise in preclinical testing and because with ex vivo methods no infectious agents are introduced directly into the patient. All genetic manipulations occur outside the body, and the transduced cells can be extensively tested for safety before reimplantation. As an additional safety measure, the genes are introduced into joints 1 week before their surgical removal for the implantation of artificial joints. This has the additional advantage of providing joint tissue for further analysis.
T o eliminate the possibility of germline transmission of the new genetic information, this trial is limited to postmenopausal women. Other inclusion criteria are a diagnosis of RA and the need for joint replacement surgery on the metacarpophalangeal joints numbers 2-4 (knuckles) of one hand and an additional surgical procedure on at least one other joint. The latter provides the opportunity to recover autologous tissue, from which synovial fibroblasts are propagated. Half of the cells are retrovirally transduced with the IL-1Ra cDNA and the other half are not. Having confirmed that the transduced cells produce sufficient IL-lRa, they and the untransduced cells are subjected to detailed safety testing before being injected into the patient's knuckle joints. Two of the knuckles receive untransduced cells, and the other two receive transduced cells. After 1 week the joints are surgically removed and the tissues examined for evidence of successful gene transfer, gene expression and a local biological response to the IL-1Ra produced from the transgene. Because of the advanced nature of the disease and the short dwell time of the gene, no clinical improvement is expected, although patients are closely monitored clinically as part of the protocol.
In January 1996, the U.S. Federal Drug Administration gave permission for nine patients to be treated in this manner. So far two have been enrolled and one treated. T h e procedure was extremely well tolerated by the patient and no adverse effects have been noted. Tissue is in the process of being analysed for evidence of successful gene transfer and expression.
Progress to date has been rapid and permits optimism that gene therapy may become a treatment option for a variety of autoimmune [ 
